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Proteins released from Mycobacterium tuberculosis (Mtb) during
late logarithmic growth phase are often considered candidate
components of immunogenic or autolysis markers. One such pro-
tein is isocitrate dehydrogenase (ICD), a key regulatory enzyme in
the citric acid cycle. We have evaluated the immunogenic proper-
ties of two isoforms of Mtb ICD and compared them with the
control antigens heat-shock protein 60 and purified protein deriv-
ative (PPD). PPD lacks the sensitivity to distinguish between bacil-
lus Calmette–Gue´rin (BCG)-vaccinated and tuberculosis (TB)-infected
populations, and, therefore, epidemiological relevance of PPD in
BCG-vaccinated regions is debatable. We show that Mtb ICDs elicit
a strong B cell response in TB-infected populations and can differ-
entiate between healthy BCG-vaccinated populations and those
with TB. The study population (n  215) was categorized into
different groups, namely, patients with fresh infection (n  42),
relapsed TB cases (n  32), patients with extrapulmonary TB (n 
35), clinically healthy donors (n  44), nontuberculous mycobac-
teria patients (n  30), and non-TB patients (culture negative for
acid-fast bacteria but carrying other infections, n  32). The Mtb
ICDs showed statistically significant antigenic distinction between
healthy BCG-vaccinated controls and TB patients (P < 0.0001) and
those with other infections. Although extrapulmonary infections
could not be discriminated from healthy controls by heat-shock
protein 60 (P  0.2177), interestingly, the Mtb ICDs could signifi-
cantly (P < 0.0001) do so. Our results highlight the immunodom-
inant, immunosensitive, and immunospecific nature of Mtb ICDs
and point to an unusual property of this tricarboxylic acid energy
cycle enzyme.
Tuberculosis (TB), caused by Mycobacterium tuberculosis(Mtb), remains a major threat to the human population,
being responsible for2–3 millions deaths every year worldwide
(1–3). The secret of the pathogen’s success is its ability to escape
the host immune system and remain undetected in lungs for
decades. In only 10% of infected people, the number being
higher in immunocompromised patients, does TB erupt as a
full-blown disease (4). Delay in diagnosis and treatment impedes
the downstream management and control of the disease. With
the increasing emergence of multidrug resistant strains and
coinfection with HIV, the problem is further compounded (5–7).
Early diagnosis, therefore, is a matter of utmost concern not just
for TB disease management but also for epidemiological inves-
tigations (8). Current diagnostic tools for TB often lack sensi-
tivity and can be time consuming. TB diagnosis in developing
countries largely banks on tuberculin skin tests and staining and
culture methods. The epidemiological relevance of the tubercu-
lin test with purified protein derivative (PPD) is questionable in
areas where bacillus Calmette–Gue´rin vaccination is compul-
sory because PPD is not sensitive enough to distinguish between
vaccinated and infected individuals (9). Microscopic determi-
nation of the bacilli in the sputum samples is a direct way of
examining pulmonary TB (5). This method, however, requires
high titers of bacilli (5,000–10,000 per ml) in sputum, a condition
seen only in full-blown TB patients. Culture techniques can
detect very low titers but are time-consuming, taking 3–6
weeks (10).
The importance of the major extracellular proteins of the
pathogen as candidate components of a subunit vaccine has
been reported earlier (11). Discovery of the RD1 locus in the
Mtb genome, encoding mainly the proteins actively secreted by
mycobacteria into the culture medium, such as CFP-10 and
ESAT-6, has further encouraged immunological tests as an
adjunct to conventional diagnosis (12–15). Proteins that are
released from Mtb during late logarithmic growth phase, such
as superoxide dismutase and isocitrate dehydrogenase (ICD),
are used as autolysis markers (16). The use of ICD as a
potential antigen for serodiagnosis along with malate dehy-
drogenase has been suggested (17, 18). The Mtb genome
carries two isoforms of ICD, Mtb ICD-1 and Mtb ICD-2.
Multiple sequence alignment revealed a closer similarity of
Mtb ICD-1 to eukaryotic NADP-dependent ICDs, whereas
Mtb ICD-2 groups with bacterial ICDs (unpublished data). We
have evaluated the utility of ICDs as immunogenic markers for
TB through the detection of anti-Mtb ICD antibodies in sera
of different well characterized categories of TB patients
through enzyme-linked immunosorbent assays. We describe
the sensitivity and specificity of ICDs to distinguish TB
patients from those vaccinated with bacillus Calmette–Gue´rin
and from those patients infected with nontuberculous myco-
bacteria (NTM) or other pathogens by means of the conven-
tional antigens, heat-shock protein 60 (HSP 60) (19) and PPD.
Materials and Methods
Cloning, Expression, and Purification of Mtb ICD-1 and Mtb ICD-2. The
ORFs corresponding to Mtb ICD-1 (Rv3339c, 1.230 kb) and Mtb
ICD-2 (Rv0066c, 2.238 kb) were PCR-amplified from the
genomic DNA of H37Rv. BamHI and HindIII restriction sites
were incorporated in the 5 end of forward and reverse primers,
respectively, for both Mtb ICD-1 and Mtb ICD-2. The primers
and parameters for thermal cycle amplification have been tab-
ulated in Table 1. The amplicons carrying the full-length Mtb
ICD-1 and Mtb ICD-2 were cloned at the BamHI and HindIII
sites of the expression vector pRSET-A (Invitrogen) with six
N-terminal histidine sequence tags. The generated constructs
setAicd1 and setAicd2 were further transformed into the BL21
(DE3) strain of Escherichia coli. The clones were confirmed by
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sequencing with the T7 promoter primer on an Applied Biosys-
tems Prism 377 DNA sequencer.
The genes were overexpressed in the pRSET-AE. coli BL-21
(DE3) expression system. The overexpressed His-tagged recom-
binant protein was purified by Ni2-nitrilotriacetate affinity
chromatography. The cells transformed with the constructs were
grown in Terrific Broth containing ampicillin (100 gml) to an
OD600 of 0.4–0.5 at 37°C, cooled to 27°C, induced with 0.1 mM
isopropyl -D-thiogalactoside, and grown overnight at 27°C. The
cells were lysed by sonication, followed by centrifugation at
16,000  g for 30 min at 4°C. The clear lysate was loaded onto
a Ni2-nitrilotriacetic acid column, which was then washed with
50 mM NaH2PO4300 mM NaCl20 mM imidazole, pH 8. The
protein was eluted in the same buffer supplemented with 200
mM imidazole. The proteins were 90–95% pure as seen on 10%
SDSPAGE followed by Coomassie blue staining (Fig. 1). The
purified recombinant proteins were dialyzed against 20 mM
TrisHCl, pH 7.5, with 100 mM NaCl and 3% glycerol and
quantified by using Bradford reagent (20).
Human Sera. The study population (n  215) comprised the
Mtb-infected human sample population reporting to the Mahavir
Hospital and Research Centre and the Central JALMA Institute
for Leprosy. These populations were categorized into three groups,
namely Group 1 (n 42 patients), Group 2 (n 32 patients), and
Group 3 (n  35 patients). In addition to the above, 44 clinically
healthy donors, 30 NTM cases, and 32 non-TB patients who were
proven culture-negative for acid-fast bacteria were also included as
controls in this study. Group 1 comprised patients with fresh
infection with no history of TB treatment. Group 2 comprised
patients with relapsed cases, i.e., those who were treated earlier for
TB but whose symptoms reemerged after the completion of the
treatment. Group 3 included patients with extrapulmonary TB.
Patients from Groups 1 and 2 were diagnosed by sputum exami-
nation (acid-fast bacillus smear positive and negative), whereas the
extrapulmonary cases were confirmed by tissue biopsy. Clinically
healthy donors were Mycobacterium bovis bacillus Calmette–
Gue´rin-vaccinated and had no symptoms of TB at the time of sera
collection. Randomly picked individuals from the population of
healthy controls were subjected to a PCR test for TB and were
found to be PCR-negative. Mycobacteria other than Mycobacterium
leprae that are not included in the Mtb complex are referred to as
NTMs (21). However, the group referred to as NTMs in this study
included sera collected from patients infected with NTM species
(n 14), such as Mycobacterium avium, Mycobacterium xenopi, and
Mycobacterium fortuitum, as well as sera from patients with M.
leprae infection (n  16). The non-TB patient category included
infected individuals who were tested negative for acid-fast bacteria
by staining and culture-based techniques. These patients were also
negative for HIV and hepatitis B virus. These randomly picked
patients were suffering from pneumonia, lower respiratory infec-
tions, septicemia, urinary tract infections, gastrointestinal infec-
tions, cirrhosis, or fever of unknown origin. The study population
had no sex or age bias. This study was approved by the Institutional
Ethics Committee.
Immunosorbent Assays. ELISAs were performed to check the B
cell immune response in humans to the Mtb ICD-1 and ICD-2
proteins and control antigens HSP 60 and PPD. The HSP 60 used
was Mtb HSP65GroEL. In brief, the 96-well microtiter plates
(Costar) were coated with 500 ng of either control antigens or
recombinant Mtb ICD-1 and Mtb ICD-2. The plates were
incubated overnight at 4°C, washed three times with PBS, and
blocked with 100 l of blocking buffer (2% BSA in PBS) for 2 h
at 37°C. The plates were then washed three times with wash
buffer PBST (0.05% Tween 20 in 1 PBS). The Mtb-infected
human sera belonging to different clinical groups were diluted
200 times in blocking buffer (1% BSA in PBS). Serum (50 l)
was added to antigen-coated wells and then incubated for 1 h at
Table 1. PCR primers and thermal cycle parameters for amplification of Mtb ICD-1 and ICD-2
Primer Sequence PCR parameters Amplicon size
Mtb icd-1
forward ggatccATGTCCAACGCACCCAAGATA 94°C for 2 h 1.2 kb
reverse aagcttCTAATTGGCCAGCTCCTTTTC 35 cycles:
94°C for 30 min,
50°C for 1 h,
72°C for 3 h,
72°C for 7 h
Mtb icd-2
forward AGCTTggatccATGAGCGCCGAACAGCC 94°C for 2 h 2.23 kb
reverse CATGGaagcttTCAGCCTTGGACAGCCT 10 cycles:
94°C for 30 min,
50°C for 30 min,
72°C for 3.5 h
25 cycles:
94°C for 30 min,
72°C for 3.5 h,
72°C for 7 h
Fig. 1. Affinity purification of Mtb ICD-1 and Mtb ICD-2. His-tagged recom-
binant protein was purified by nickel column chromatography under native
conditions and stained with Coomassie blue after 10% SDSPAGE. Lanes: 1
and 2, Mtb ICD-2; M, protein molecular mass markers (200, 116 , 97, 66, 45, 31,
and 21.5 kDa); 3 and 4, Mtb ICD-1.
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37°C. The plates were thoroughly washed with PBST and further
incubated with anti-human IgG-horseradish peroxidase (Sigma)
at 37°C for 1 h. Horseradish peroxidase activity was detected by
using a chromogenic substance, o-phenylenediamine tetrahydro-
chloride (Sigma), in citrate-phosphate buffer (pH 5.4) and H2O2
(Qualigens Fine Chemicals, Ahmedabad, India) as 1 lml. The
reactions were terminated by using 0.5 M H2SO4, and the
absorbance values were measured at 492 nm in an ELISA reader
(Bio-Rad). Each ELISA was repeated at least twice with some
randomly picked serum samples tested three times for confir-
mation, with and without replicates for each sample within
individual ELISA.
Data Analysis. Student’s t test was performed to compare the means
of two variable groups, healthy and infected classes, by using the
online scientific calculator of GraphPad (www.graphpad.com
quickcalcsttest1.cfm) to calculate means, SEM, and P values.
Results
Expression and Purification of Mtb ICD-1 and Mtb ICD-2. The over-
expressed N-terminal His-tagged Mtb ICD-1 was purified to 95%
homogeneity on a nickel affinity column (Fig. 1). The molecular
mass of the recombinant ICD-1 was determined to be 49.2 kDa.
The purification was carried out under native conditions from
soluble fractions with an yield of 3.25 mg of protein per 500 ml
of start culture. Similarly Mtb ICD-2, an 83-kDa protein, was
purified to 90–95% homogeneity (Fig. 1) with a yield of 20.4
mg per 1,000 ml of start culture.
Mtb ICD-1 and Mtb ICD-2 Show High Reactivity to Patient Sera As
Opposed to Bacillus Calmette–Gue´rin-Vaccinated Healthy Controls.
Humoral immune responses directed against the Mtb ICD-1 and
Mtb ICD-2 were compared among patients with TB and bacillus
Calmette–Gue´rin-vaccinated healthy controls (Fig. 2 A and B).
The recombinant proteins were used to screen the infected and
healthy sera by ELISA using anti-human IgG-horseradish per-
oxidase as a conjugate. The sera were also tested against Mtb
HSP 60 and the PPD (Fig. 2 C and D). The immunoreactivity of
ICD-1, ICD-2, HSP 60, and PPD was statistically analyzed and
compared with respect to both infected and healthy sera. These
data demonstrate that sera of all of the infected patients
mounted a statistically significant (P  0.0001) antibody re-
sponse against recombinant Mtb ICD-1 and Mtb ICD-2 proteins
as compared with that of the healthy controls. PPD, on the other
hand, reacted against both healthy and TB-infected sera. It is
interesting to note that, compared with ICD-1 and ICD-2 (P 
0.0001), the difference in the reactivity of PPD to total infected
and healthy sera was negligible and statistically insignificant (P
0.2301). Because PPD, a mixture of proteins, showed statistically
insignificant discrimination between healthy populations and
different categories of infected populations (Fig. 2D), the reac-
tivities of the recombinant proteins were compared with the B
Fig. 2. Mtb ICD-1 and ICD-2 show high B cell reactivity to sera from TB-infected patients from different groups as opposed to bacillus Calmette–Gue´rin-
vaccinated healthy controls. The humoral immune responses directed against the recombinant proteins Mtb ICD-1 (A) and Mtb ICD-2 (B) and control antigens
HSP 60 (C) and PPD (D) were compared among different categories of patients and healthy controls. Group 1, fresh infections; Group 2, relapsed infection; Group
3, extrapulmonary TB. The respective sample numbers and P values are shown.
12654  www.pnas.orgcgidoi10.1073pnas.0404347101 Banerjee et al.
cell response to Mtb HSP 60 (Fig. 2C) in different categories of
patients. The difference between reactivity to HSP 60 between
TB patients and healthy controls was statistically not quite
significant (P  0.0645).
A correlation between reactivity against Mtb ICD-1 and Mtb
ICD-2 in patient sera with the state of disease, fresh or relapse,
was attempted by comparing the antibody responses to Mtb
ICD-1 and Mtb ICD-2 of various clinical categories (Fig. 2 A and
B, respectively). Mtb ICD-1 failed to discriminate between fresh,
relapsed, and extrapulmonary TB cases because no significant
differences in immunoreactivity in different patient groups were
observed (Fig. 2 A). Yet compared with bacillus Calmette–
Gue´rin-vaccinated healthy controls each category yielded P
values 0.0001, indicating that Mtb ICD-1 can differentiate
substantially between bacillus Calmette–Gue´rin-vaccinated
healthy populations and any category of Mtb-infected patients,
pulmonary or nonpulmonary. Mtb ICD-2, on the other hand,
could also discriminate relapsed cases from both fresh infections
(P  0.0001) and extrapulmonary infections (P  0.0003). Like
Mtb ICD-1, Mtb ICD-2 could also distinguish substantially
between bacillus Calmette–Gue´rin-vaccinated healthy popula-
tion and any category of Mtb-infected patients. Surprisingly, HSP
60, although it could discriminate Groups 1 and 2 from healthy
controls (P  0.0011 and 0.0036, respectively), failed to distin-
guish the extrapulmonary infections from bacillus Calmette–
Gue´rin-vaccinated healthy controls (P  0.2177). These results
demonstrate that (i) recombinant Mtb ICD-1 and ICD-2 proteins
could differentiate sera from TB-infected patients by means of
healthy bacillus Calmette–Gue´rin-vaccinated controls, (ii) the
extrapulmonary infections that could not be distinguished from
healthy controls by HSP 60 could be significantly identified and
categorized by Mtb ICDs, and (iii) Mtb ICD-2 mounted a
stronger antibody response in relapsed cases and could signifi-
cantly discriminate them from Group 1 and Group 3. These
proteins, which have an apparently important metabolic role, are
thus able to elicit a strong B cell response as a function of the TB
infection.
Immunodominace of ICDs over HSP 60. We compared the immu-
nogenicity of ICDs over HSP 60. Humoral response to HSP 60
in all of the three categories of TB patients was tested and
compared with those to ICDs (Fig. 3). The data clearly indicate
that the mean reactivity (represented by the horizontal bands in
Fig. 3) of HSP 60 in all of the classes of patient sera was much
lower than in either ICD-1 or ICD-2 (Fig. 3). Thus, ICDs are
immunodominant and serologically more sensitive than HSP 60.
The mean values for ICD-1 in Groups 1, 2, and 3 were 0.481,
0.565, and 0.457, respectively, whereas those for ICD-2 were
0.165, 0.362, and 0.188, respectively. It is therefore apparent that
ICD-1 elicited a stronger response in all of the three categories
of patients tested than ICD-2. The data also confirm the
discriminatory power of ICD-2 for relapsed case as compared
with other categories.
Immunospecificity of Mtb ICDs. The potential of Mtb ICDs to
specifically distinguish between TB, NTMs, and non-TB patient
sera (those essentially culture-negative for acid-fast bacteria but
harboring other pathogens) was tested by examining the cross-
reactivity of the recombinant proteins with NTMs and non-TB
patient sera. Thirty NTMs and 32 non-TB patient sera were
tested for their immunogenic response against Mtb ICD-1, Mtb
ICD-2, and HSP 60. The data were statistically analyzed to check
whether ICDs could significantly distinguish between TB-
infected patients and NTMs or non-TB patients. Fig. 4 shows
that ICDs could significantly distinguish TB-infected sera from
NTMs (P  0.0001) and non-TB patients (P  0.0001 for ICD-1
and P  0.0008 for ICD-2), thus ruling out any crossreactivity
with NTMs and other bacterial pathogens tested. HSP 60
appeared to react more broadly to the population under study
and could not differentiate between TB infections and NTMs
(P  0.4461) or non-TB cases (P  0.3464) significantly. That
HSP 60 reacted broadly was apparent by calculating the average
reactivity for each group (infected, NTMs, and non-TB), for
which reactivity to HSP 60 remained almost the same (Fig. 4).
The mean reactivity for HSP 60 is in contrast to the mean
Fig. 3. Mtb ICDs are more immunogenic than HSP 60. The ELISA reactivity to Mtb ICD-1, Mtb ICD-2, and control antigen HSP 60 was compared in different patient
groups. Horizontal bands represent the mean reactivity or average levels of humoral response in each category.
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humoral response to ICD-1 and ICD-2, for which a distinctly
higher response was seen in TB-infected sera as compared with
NTMs or non-TB cases.
Discussion
The main objective of our study was to evaluate Mtb ICD-1 and
Mtb ICD-2 in terms of their immune features as compared with
the control antigens, HSP 60 and PPD, that are frequently used
for diagnosis of TB. ICDs serve as markers of autolysis (16, 17)
and are among the secretory proteins released during the late
logarithmic phase. Although earlier efforts have pointed to the
antigenic potential of Mtb ICDs (17), the present study is
systematic investigation of their potential as an immune marker.
The cases of TB were identified and enrolled based on their
history of treatment as fresh infections, relapsed cases, and
extrapulmonary infections. The categorization of patients largely
depended on the treatment history dictated by the patients or
their family members. As evident from Fig. 2, there is little doubt
about the ability of either Mtb ICD-1 or Mtb ICD-2 to elicit a
strong B cell response, irrespective of patient category. When
compared with Mtb ICD-2, Mtb ICD-1 was more antigenic (Figs.
2 and 3). It would be interesting to explore this disparity. A
comparative analysis of ELISA reactivities among different
categories of patients for Mtb ICDs (Fig. 2 A and B) revealed
higher reactivity in Group 2 as compared with fresh (Group 1)
and extrapulmonary (Group 3) infections. More specifically, the
antigenic response in this category of patients to ICD 2 was
significantly higher than that in Group 1 and Group 3. Because
these patients had undergone treatment earlier, a high number
of autolysed infected macrophages and autolysed pathogens
could possibly explain the comparative high-antibody response
against Mtb ICDs in this category. Drugs, like isoniazid, are
known to affect the cell envelope architecture of mycobacteria
and, hence, the increase in the production of the secreted
proteins (22).
Comparative immunoreactivity of Mtb ICD-1, Mtb ICD-2, and
HSP 60 clearly indicates that the antigenic distinction between
healthy and TB patients is statistically significant for both Mtb
ICD-1 and Mtb ICD-2 (P 0.0001) but not quite so for HSP 60 (P
0.0645). Earlier reports have shown crossreactive epitopes between
microbial HSP 6065 and human HSP 60, which often serve as
autoimmune targets in conditions like atherosclerosis (19). The
crossreactive epitopes probably could explain the broader reactivity
of HSP 60 to healthy and infected sera. Because negligible antibody
responses were obtained in the bacillus Calmette–Gue´rin-
vaccinated healthy control group as compared with TB-infected
patients and because a statistically significant difference in the
immunoreactivity between infected and healthy sera was observed,
it can be argued that Mtb ICD-1 and Mtb ICD-2 can be used for
diagnosis of Mtb infection even in areas where bacillus Calmette–
Gue´rin vaccination is routinely followed. The poor performance of
PPD can be attributed to its nonspecific immune reaction in bacillus
Calmette–Gue´rin-vaccinated healthy controls. Interestingly, the
extrapulmonary TB cases (Group 3) in the study population did not
show any significant humoral response to HSP 60 to distinguish
them from healthy controls. On the other hand, Group 3 patients
mounted a very significant B cell response to ICD-1 and ICD-2,
separating them from bacillus Calmette–Gue´rin-vaccinated healthy
controls.
Immunodominance is a parameter that we defined to compare
the antibody titers against the tested proteins, i.e., ICD-1, ICD-2,
and HSP 60, in the patient sera. Our data clearly showed that
ICD-1 was most antigenic and mounted a very strong B cell
response in all of the patient categories, followed by ICD-2 and
HSP 60 (Fig. 3). Having shown that Mtb ICDs elicit a B cell
response much higher than HSP 60, we checked for immune
specificity of these proteins. Crossreaction with sera of NTMs
and non-TB patients is one of the critical parameters that needed
to be checked before establishing any antigenic marker for
possible serological studies in Mtb. Mtb complex, including M.
bovis and Mycobacterium africanum, is responsible for more
illness worldwide than any other bacteria. However, there are
82 recognized species of mycobacteria that occasionally infect
mammalian hosts. These species, referred to as NTMs, are
omnipresent in the environment, and most species are either
nonpathogenic for humans or are rarely associated with disease,
except for a few, like M. avium, that are opportunistic pathogens,
more frequently associated with immunocompromised patients
(23, 24). The clinical significance of many NTMs remains
unclear; however, it is important to check the crossreactivity of
Fig. 4. Mtb ICDs could significantly distinguish TB-infected sera from NTMs and non-TB patient sera. Recombinant Mtb ICD-1 and Mtb ICD-2 and HSP 60 were
tested against sera of NTM (A) and non-TB (B) patients. The respective humoral responses were compared with those for TB-infected sera, the P values for which
are shown. HSP 60 could not distinguish TB-infected patients from either NTM or non-TB patients significantly. Horizontal bands represent the mean reactivity
in each category.
12656  www.pnas.orgcgidoi10.1073pnas.0404347101 Banerjee et al.
Mtb antigens with this group of mycobacteria. Our experiments
could establish that Mtb ICDs do not crossreact with either
NTMs or non-TB patient sera (Fig. 4).
The existing diagnostic tests for TB, even to this day, largely
depend on tuberculin skin tests and staining and culture tech-
niques. These methods are slow, cumbersome, and lack sensi-
tivity and specificity in bacillus Calmette–Gue´rin-vaccinated
cases. As more and more recombinant antigens are being tested
(25–31), serological methods are likely to be favored over others.
ELISA per se is unlikely to replace the current TB diagnosis;
however, in combination or parallel with other rapid PCR-based
diagnostic techniques, ELISA can largely improve the accuracy
and rapidity of TB diagnosis for an effective disease manage-
ment. Our data reveal the antigenic potential of recombinant
Mtb ICD-1 and also present a systematic study on immunoge-
nicity of recombinant Mtb ICD-2. Mtb ICD-1 and Mtb ICD-2 can
be further analyzed for their pathogen-specific antigenic
epitopes. Given their important role in the energy cycle, an
evaluation of these two Mtb enzymes as possible drug targets is
necessary. That such important enzymes can also have strong
antigenic attributes that enable them to significantly discrimi-
nate between bacillus Calmette–Gue´rin-vaccinated healthy con-
trols and TB patients and at the same time TB from other
pathogenic infections is a very exciting proposition, possibly
pointing to their immunomodulatory function.
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